Abstract-Lewy body diseases involve neurogenic orthostatic hypotension (nOH), cardiac noradrenergic deficiency, and deposition of the protein AS (alpha-synuclein) in sympathetic ganglion tissue. Mechanisms linking these abnormalities are poorly understood. One link may be AS deposition within sympathetic neurons. We validated methodology to quantify AS colocalization with TH (tyrosine hydroxylase), a marker of sympathetic noradrenergic innervation, and assessed associations of AS/TH colocalization with myocardial norepinephrine content and cardiac sympathetic neuroimaging data in nOH. Postmortem sympathetic ganglionic AS/TH colocalization indices and myocardial norepinephrine contents were measured in 4 Lewy body and 3 rare non-Lewy body nOH patients. Sixteen Lewy body and 11 non-Lewy body nOH patients underwent in vivo skin biopsies and thoracic 18 F-dopamine positron emission tomographic scanning, with cutaneous colocalization indices expressed versus cardiac 18 F-dopamine-derived radioactivity. Ganglionic AS/ TH colocalization indices were higher and myocardial norepinephrine lower in Lewy body than non-Lewy body nOH (P=0.0020, P=0.014). The Lewy body nOH group had higher AS/TH colocalization indices in skin biopsies and lower myocardial 18 F-dopamine-derived radioactivity than did the non-Lewy body nOH group (P<0.0001 each). All Lewy body nOH patients had colocalization indices >1.5 in skin biopsies and 18 F-dopamine-derived radioactivity <6000 nCikg/cc-mCi, a combination not seen in non-Lewy body nOH patients (P<0.0001). In Lewy body nOH, AS deposition in sympathetic noradrenergic nerves is related to postmortem neurochemical and in vivo neuroimaging evidence of myocardial noradrenergic deficiency. These associations raise the possibility that intraneuronal AS deposition plays a pathophysiological role in the myocardial sympathetic neurodegeneration attending Lewy body nOH. 
O rthostatic hypotension (OH) occurs commonly in the elderly, 1 is associated with decreased quality of life and increased morbidity and mortality, 2 and is treatable. 3 Neurogenic OH (nOH) is a form of OH that results from inadequate reflexive release of the sympathetic neurotransmitter norepinephrine (NE) in response to upright posture. 4 Symptoms of nOH can be improved by NE precursor therapy, 5 especially in the setting of sympathetic noradrenergic deficiency. 6 Prominent among causes of nOH are Lewy body diseases, such as Parkinson disease (PD), dementia with Lewy bodies (DLB), and pure autonomic failure (PAF). These diseases involve severe myocardial NE depletion 7 and postmortem evidence for deposition of the protein AS (alpha-synuclein) in catecholaminergic neurons both in the brain and in the sympathetic nervous system. 8, 9 In contrast with Lewy body diseases, multiple system atrophy (MSA), which usually also involves nOH, is characterized by AS deposits in glial cells in the central nervous system. 10 Lewy body diseases and MSA are now considered to be members of a family of autonomic synucleinopathies. 11 Bases for the relationship between alpha-synucleinopathy and myocardial noradrenergic deficiency are poorly understood. In rare patients with autosomal dominantly transmitted familial PD, mutation or replication of the gene encoding AS causes not only the characteristic movement disorder but also nOH, accompanied by neuroimaging evidence of myocardial sympathetic denervation. 12, 13 Although postmortem observations have documented that sporadic Lewy body diseases are associated with cardiac sympathetic denervation, 14, 15 the relevance to these findings of AS deposition within sympathetic nerves is unclear.
Denervation may not be the only determinant of myocardial noradrenergic deficiency. Under resting conditions, most of tissue catecholamine turnover reflects net leakage from the vesicles into the cytoplasm. 16 Lewy body diseases are associated with high catecholamine turnover because of decreased vesicular sequestration and a shift from vesicular sequestration to oxidative deamination of cytoplasmic catecholamines in myocardial sympathetic nerves. [17] [18] [19] These functional abnormalities would be expected to contribute to myocardial noradrenergic deficiency and could augment formation of toxic products of oxidation of cytoplasmic catecholamines, such as 3,4-dihydroxyphenylacetaldehyde. 20 In the present study, we used the mono-exponential slope of decline of 18 F-dopamine-derived radioactivity between the frames with midpoints about 8 minutes and 25 minutes after initiation of tracer injection (k8'-25') as an index of myocardial catecholamine turnover. Studies to date have not assessed the relationship between myocardial catecholamine turnover and intraneuronal AS deposition.
A key deficiency in this area has been the lack of a method to quantify AS deposition in sympathetic noradrenergic nerves. Immunofluorescence microscopic assays have been used to visualize AS in skin biopsies from patients with autonomic synucleinopathies, 11, [21] [22] [23] but differences in methodologies and inconsistencies in results remain to be resolved, 21, [24] [25] [26] and the reports have usually been observational or semiquantitative. 11 Under the presumption that sympathetic denervation may decrease tissue AS content because of the deposition of AS within sympathetic nerve fibers that are lost, an "alphasynuclein ratio" has been proposed, in which AS signal in regions of interest is adjusted for local innervation by the ratio of AS to protein gene product 9.5, known as PGP 9.5, which is a pan-axonal marker. 27 No previous study has validated and applied methodology to measure AS deposition within sympathetic noradrenergic nerves.
We devised and validated methodology to quantify colocalization of AS with TH (tyrosine hydroxylase), a marker of sympathetic noradrenergic innervation; and we examined whether AS/TH colocalization in sympathetic ganglion tissue postmortem is related to myocardial NE depletion and whether AS/TH colocalization in skin biopsies in vivo is related to neuroimaging evidence of cardiac sympathetic denervation and dysfunction in Lewy body nOH.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Subjects
The subjects in this study were evaluated at the National Institutes of Health (NIH) Clinical Center after having given written informed consent to participate in one or more research protocols approved by the Intramural Research Board of the National Institute of Neurological Disorders and Stroke. Patients had been referred for evaluation of a known or suspected autonomic synucleinopathy. Five healthy control subjects were also studied. Autonomic function testing to identify nOH included continuous blood pressure recording associated with performance of the Valsalva maneuver 28 and orthostatic plasma catechols.
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Lewy Body nOH PAF (N=9) was diagnosed based on nOH in patients more than 30 years old without signs of central neurodegeneration, low plasma levels of NE or its neuronal metabolite DHPG (3,4-dihydroxyphenylglycol), 30 and low myocardial 18 F-dopamine-derived radioactivity.
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Such patients also often have olfactory dysfunction. 32 Patients with nOH in the setting of DLB (N=2) carried an initial diagnosis of PAF but developed dementia and parkinsonism over years. The patients had a putamen/occipital cortex ratio of
33 and low myocardial 18 F-dopamine-derived radioactivity. PD with orthostatic hypotension (PD+OH, N=5) was diagnosed from nOH, bradykinesia and cogwheel rigidity, low myocardial 18 F-dopamine-derived radioactivity, and a putamen/occipital cortex ratio of 18 F-DOPA-derived radioactivity ≤2.4.
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Non-Lewy Body nOH
MSA (N=6) was diagnosed by progressive parkinsonism or cerebellar ataxia and other supportive clinical features, such as poor airway control manifested by dysarthria, stridor, or aspiration and urinary retention requiring bladder catheterization. The patients had decreased cerebrospinal fluid levels of DOPAC (3,4-dihydroxyphenylacetic acid) 34 and normal interventricular septal myocardial 18 F-dopamine-derived radioactivity. 17, 31 Among the group of patients with rare non-Lewy body forms of nOH, there were 2 with autoimmune autonomic ganglionopathy, diagnosed by symptoms of pandysautonomia, neuroimaging evidence of intact postganglionic sympathetic innervation, and high titers of antineuronal nicotinic receptor antibodies. 35, 36 Other patients with non-Lewy body nOH had autoimmunity-associated autonomic failure with sympathetic denervation (N=1), 37 baroreflex failure after neck and chest irradiation for lymphoma in the remote past (N=1), 38 or PAF with autopsy-proven absence of Lewy bodies in the brain and sympathetic ganglion tissue (N=1).
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Assay Validation
In order to validate AS deposition in sympathetic noradrenergically innervated skin constituents and the AS/TH colocalization index as biomarkers of Lewy body forms of nOH, we comprehensively studied patients diagnosed with PD+OH, PAF, or DLB+OH as described above. Seven patients (4 with Lewy body nOH, 3 with non-Lewy body nOH) had postmortem confirmation of their diagnoses. The AS/ TH colocalization index was validated further in sympathetic ganglion tissue obtained postmortem from Banner Sun Health Research Institute-4 patients with autopsy-proven Lewy body disease and 4 controls without a Lewy body disease.
To exclude nonspecific binding of AS antibody, AS was analyzed in samples from rare patients with nOH who would not be expected to have AS deposition in sympathetic noradrenergically innervated skin constituents. The negative controls included 2 patients with autoimmune autonomic ganglionopathy, where nOH reflects circulating antibodies to the neuronal nicotinic receptor, 36 a patient with autoimmunity-associated autonomic failure with sympathetic denervation, 37 a patient who had autopsy-proven PAF without synucleinopathy in the brain or sympathetic ganglion tissue, 39 and 5 healthy volunteers. To exclude nonspecific binding of TH antibody, immunoreactive TH was measured in the patient with autoimmunity-associated autonomic failure with sympathetic denervation, who had extremely low plasma and urine levels of catechols and no measurable TH in skin biopsy tissues assayed in our laboratory and independently in another laboratory. 37 To adjust for possible concurrent sympathetic noradrenergic denervation or atrophic changes in the sizes of sympathetic noradrenergically innervated skin constituents, AS signal intensity was expressed both in absolute terms and relative to TH or SMA (smooth muscle actin) in the same images.
Skin Biopsies
There are obvious individual and ethnic differences in hair distribution, cutaneous vascularity, and sweating along the lateral aspect of the leg-the usual site of skin biopsies-whereas the nape of the neck has relatively abundant hair, blood vessels, and sweat glands. In this study, skin biopsies were obtained from the lateral aspect of the leg in 2 patients before the biopsy location was switched to the neck.
Although eccrine sweat glands are well known to receive sympathetic cholinergic innervation, they also receive sympathetic noradrenergic innervation. [40] [41] [42] [43] The central hypothesis driving our study, that AS deposition within sympathetic noradrenergic nerves is associated with cardiac noradrenergic deficiency in patients with nOH, explains the emphasis on colocalization of AS with immunoreactive TH in nerve fibers surrounding sweat glands.
Skin biopsy samples were placed in Zamboni fixative solution and kept at 4°C for about 18 to 20 hours, washed with Sorenson phosphate buffer (133 mmol/L, pH 7.6), and placed in 20% glycerol for cryoprotection. Samples were embedded in optimum cutting temperature compound, frozen, and sliced into 8-10 μm thick sections (Histoserv, Germantown, MD).
SMA-containing and sympathetic noradrenergic fibers are arranged in parallel in arrector pili muscles. In eccrine sweat glands, SMA surrounds the secretory epithelial cells, and sympathetic noradrenergic nerves surround the SMA. In blood vessels, sympathetic noradrenergic nerves surround the SMA. These characteristic features enabled identification of even small pieces of arrector pili, blood vessels, and sweat glands in the relatively thin sections.
Immunolabeling protocols were applied to identify TH using rabbit anti-TH antibody (1:1000; Pel-Freez Biologicals, Rogers, AR), AS using mouse IgG 1 monoclonal anti-AS (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), and alpha SMA using mouse IgG 2a monoclonal anti-SMA (1:400; Santa Cruz Biotechnology, Santa Cruz, CA) for 24 hours at 4°C. The primary immunoreactions were visualized using appropriate secondary antibodies-Cy3-conjugated anti-rabbit antibody (Jackson Immune Research Labs), Alexa 488-conjugated anti-mouse IgG 1 antibody and Alexa 647-conjugated anti-mouse IgG 2a antibody (Thermo Scientific, Inc, Rockford, IL) for 1 hour at room temperature. Coverslips were mounted on slides with ProLong Gold antifade reagent (Thermo).
To minimize nonspecific binding, the immunostained tissues were treated with TrueBlack Lipofuscin Autofluorescence Quencher (Biotium, Inc, Fremont, CA). The tissues mounted on slides were subjected to confocal immunofluorescence microscopy using a Zeiss LSM 880 laser scanning microscope (Carl Zeiss, Germany). The images were captured using proprietary ZEN 2 image acquisition, and the image datasets were processed for image stitching and illumination correction (Zeiss).
Fluorescence intensities were in relative units. We included a negative control on each slide and used the same laser gain and sensitivity settings for all the samples. All the images were analyzed by personnel who were blinded as to the individual clinical diagnosis. For skin biopsies, image sizes were 1024×1024 pixels. Image analysis procedures are described below.
F-Dopamine Positron Emission Tomographic Scanning
18 F-dopamine positron emission tomographic scanning was done as described previously. 44 Briefly, interventricular septal and free wall concentrations of 18 F-dopamine-derived radioactivity were recorded for the 5-minute frame with a midpoint about 8 minutes after initiation of the 3-minute infusion of 1 mCi of the tracer (8' Radioactivity). Radioactivity concentrations in nCi/cc were adjusted for the radioactivity dose in mCi and the body mass in kg and expressed in units of nCi-kg/cc-mCi. The radioactivity normally peaks at about 8 minutes.
To calculate the rate of loss of radioactivity between the frame with the midpoint at 8 minutes and the 10-minute frame with midpoint at 25 minutes after initiation of tracer administration, we obtained the mono-exponential slope of decline in septal radioactivity (k8'-25'). This slope indicates pharmacokinetic turnover, probably as an inverse measure of vesicular storage.
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Other Clinical Laboratory Tests 18 F-DOPA scanning without carbidopa pretreatment was conducted as previously published. 33 Lumbar puncture was performed to obtain cerebrospinal fluid for assays of contents of catechols in our laboratory. 34 Clinical 3.0 Tesla magnetic resonance imaging was done without administration of contrast. The matrix was 240×240 pixels. There were 181 slices, each 1.0 mm thick.
The UPSIT (University of Pennsylvania Smell Identification Test; Sensonics International, Haddon Heights, NJ), Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale (off levodopa) were administered in most patients.
Postmortem Observations
Postmortem neuropathologic diagnostic confirmation was obtained for a total of 15 individuals. For 4 patients with Lewy body disease and 4 controls without a Lewy body disease, postmortem neuropathologic descriptions were provided by the Banner Sun Health Research Institute. The remaining 7 patients (4 Lewy body nOH, 3 non-Lewy body nOH) had postmortem diagnostic confirmation through the University of Miami Brain Endowment Bank or the Laboratory of Pathology at the NIH Clinical Center. Postmortem intervals were less than 24 hours in each case. AS/TH colocalization indices in sympathetic ganglion tissue were calculated and assays of myocardial NE 19 conducted.
Data Analysis and Statistics
Regions of interest were drawn (white dotted outlines) around arrector pili muscles ( Figure 1A and 1D ), blood vessels ( Figure 1B and 1E), and sweat glands ( Figure 1C and 1F) . Average fluorescence intensity of AS (green), SMA (blue), and TH (red) within the regions of interest was measured using Fiji software after background subtraction and tabulated for each visualized constituent. For colocalization analyses, the method of Jaskolski et al 45 was used, with calculation of the AS/TH colocalization index in the entire image as follows: (1) normalized mean deviation product (nMDP) values for colocalization were tabulated from −1.0 to +1.0 ( Figure 2A) ; (2) the counts corresponding to nMDP values from 0.3 to 1.0 were summed (red or blue boxes in Figure 2A) ; (3) 0.1 was added so that the sum of the counts was greater than zero; and (4) the log of the number from step (3) was calculated. The formula for the colocalization index, therefore, was the following.
Colocalization index=Log (0.1+sum nMDP 0.3 to 1.0 ) Mean values (±1 SEM) for AS, AS/TH ratios, and AS/SMA ratios for each of the 3 skin constituents and for myocardial NE contents were compared between the Lewy body nOH and non-Lewy body nOH groups by independent-means t tests conducted on log-transformed data. Student t tests were also used to compare mean values for 18 F-dopamine-derived radioactivity and clinical and other laboratory parameters between the Lewy body nOH and non-Lewy body nOH groups. Frequencies of values in compared groups were analyzed by Fisher exact test. A P value <0.05 defined statistical significance.
Results
AS/TH Colocalization Index in Postmortem Tissues
In all 8 patients with Lewy body diseases who had postmortem sympathetic ganglion tissue assayed, the AS/TH colocalization index exceeded 2.9, whereas in all 7 patients with non-Lewy body diseases, the AS/TH colocalization index was below 1.0 (P=0.00016; Figure 2B ). The mean AS/TH colocalization index in the 4 patients with Lewy body nOH was greater than the mean index in the 7 controls without a Lewy body disease (3.79±0.68 versus −0.39±0.79; P<0.0001) and than in the 3 patients with non-Lewy body nOH (−0.06±0.52, P=0.04; Table 1 ).
The 4 patients with Lewy body nOH had lower mean myocardial NE content than the 7 controls without a Lewy body disease (0.026±0.010 versus 2.17±0.87 pmol/mg wet weight; P=0.00047) and than the 3 patients with non-Lewy body nOH (3.59±1.86 pmol/mg; P=0.014; Figure 2C ).
AS Deposition in Skin Biopsies
All patients with a Lewy body form of nOH had AS deposition in arrector pili muscles, blood vessels, and sweat glands At the bottom of A is the formula used to calculate the colocalization index. Counts for nMDP values above 0.3 were summed, and 0.1 was added to the sum to avoid taking the log of zero when the sum of counts was zero. If there were no AS/TH colocalization, the index would be −1.0 (the log of 0.1). B shows individual AS/TH colocalization indices from 8 patients with a Lewy body disease (red) and 7 control subjects without a Lewy body disease (blue). C shows a scatterplot relating individual values for the AS/TH colocalization index as a function of the log of the apical myocardial concentration of norepinephrine (NE), expressed in units of pmol/mg wet weight, in Lewy body nOH patients (red), non-Lewy body nOH patients (blue), and control subjects without either nOH or a Lewy body disease (gray). Note complete separation of the Lewy body nOH patients from the non-Lewy body nOH patients and control subjects in terms of both AS/TH colocalization indices and myocardial NE contents.
(examples are in Figure 1D-1F) . Individual values for intensities of AS signal in the Lewy body nOH group were above the ranges in the non-Lewy body nOH group ( Figure 3A-3C ). (One MSA patient had blood vessel AS intensity within the range of values of the Lewy body nOH group, Figure 3B) . Intensity values for AS in arrector pili muscles, blood vessels, and sweat glands of Lewy body nOH patients averaged 37, 13, and 30 times those of non-Lewy body nOH patients (P<0.0001 each; Table 2 ).
AS/TH Colocalization in Skin Biopsies
The mean AS/TH colocalization index was greater in the Lewy body nOH than in the non-Lewy body nOH group (P<0.0001; Figure 3D and Table 2 ). All the Lewy body patients had indices >1.5. Across all subjects, values for the AS/TH colocalization index correlated positively with AS intensities in arrector pili muscles, blood vessels, and sweat glands, with or without adjustment for SMA or TH (Table S1 in the onlineonly Data Supplement).
Compared to healthy controls, Lewy body nOH patients had AS intensities and AS/TH colocalization indices above the ranges of values in the healthy controls. (An exception was a healthy control with AS intensity within the range of the Lewy body nOH group in sweat glands, Figure 3C ).
F-Dopamine-Derived Radioactivity
All the patients with Lewy body nOH had 18 F-dopaminederived radioactivity <6000 nCi-kg/cc-mCi in the left ventricular free wall ( Figure 4A-4D) . The distribution of septal 18 F-dopamine-derived radioactivity in the Lewy body nOH group was broader than the distribution of free wall radioactivity ( Figure 4E ). The distribution of k8'-25' values in the Lewy body group overlapped with the distribution in the nonLewy body group ( Figure 4F ). Among the patients with nonLewy body nOH, 1 had low free wall 18 F-dopamine-derived radioactivity ( Figure 4D) , and 3 patients with non-Lewy body nOH had septal radioactivity within the range of values in the Lewy body group ( Figure 4E) .
When individual values for AS in the 3 skin constituents were expressed as a function of 18 F-dopamine-derived radioactivity in the left ventricular free wall, the patients with Lewy body nOH were completely separated from the patients with non-Lewy body nOH ( Figure 4A-4C ). All the Lewy body nOH patients had high AS/TH colocalization indices and low free wall and septal 18 F-dopamine-derived radioactivity, a combination not seen in any of the non-Lewy body nOH patients (Figure 4D and 4E; P<0.0001 ).
Other Clinical Laboratory Data
Scores on the UPSIT distinguished the Lewy body nOH from the non-Lewy body nOH groups (Table 2) . Of the 16 patients in the former group, 10 (63%) were anosmic, a finding not observed in the latter group. Of 14 patients in the Lewy body nOH group who had a magnetic resonance imaging scan, cortical atrophy was reported in 12, whereas cortical atrophy was not reported in the 9 non-Lewy body nOH patients who had a magnetic resonance imaging scan ( Table 2 ). The Lewy body nOH group did not differ from the non-Lewy body nOH group in mean values for the putamen/occipital cortex ratio of 18 F-DOPA-derived radioactivity, washout of putamen 18 F-DOPA-derived radioactivity, or the posterior/anterior ratio of putamen 18 F-DOPAderived radioactivity (Table 2) .
Cerebrospinal fluid levels of DHPG and NE were lower in the Lewy body nOH group than in the non-Lewy body nOH group (Table 2 ). The groups did not differ in mean cerebrospinal fluid levels of DOPA or DOPAC. Plasma levels of catechols did not distinguish the 2 groups; however, mean plasma DHPG and NE levels were lower in the Lewy body nOH group than in the healthy controls (3.95±0.34 versus 8.50±0.76 pmol/mL and 1.04±0.11 versus 3.56±0.59 pmol/ mL; P<0.0001 each).
Postmortem Data in nOH Patients
A total of 7 patients with nOH (4 Lewy body, 3 non-Lewy body) had postmortem neuropathologic confirmation of their diagnoses. Patient 1 in Table 1 carried a mutation of the gene encoding glucocerebrosidase. In this patient, PAF had evolved into DLB+OH and PD+OH. Patient 2 also had PAF evolving into DLB+OH, with PD coming on late in the disease course. Although there was a strong family history of PD, as of this writing, no genotypic abnormality has been identified. The patient had severe loss of immunoreactive TH and abundant AS fibrils in sympathetic ganglion tissue. Patient 3 had PAF clinically and by the clinical laboratory tests done at the NIH Clinical Center as described in the Methods section; postmortem neuropathology showed AS-containing Lewy bodies in the substantia nigra. Patient 4, who was not studied at the NIH, had a clinical history of autonomic failure, cognitive changes, and progressive parkinsonism. Scattered AS-positive neurites were noted in the substantia nigra, without AS-positive glial cytoplasmic inclusions.
Among the non-Lewy body nOH patients, Patient 5 in Table 1 , who was not studied at the NIH, had a clinical and postmortem neuropathologic diagnosis of MSA. The AS/TH colocalization index was normal postmortem both in sympathetic ganglion tissue and in skin (data not shown). Patient 6 had a clinical and postmortem neuropathologic diagnosis of MSA. At the NIH Clinical Center, he had normal myocardial 18 F-dopamine-derived radioactivity (data not shown). Patient 7 had PAF clinically but without Lewy bodies in the brain or sympathetic ganglion tissue. 39 The patient had normal AS/TH colocalization indices in both sympathetic ganglion tissue obtained postmortem and in skin biopsies obtained during life.
Discussion
Mechanisms linking Lewy body diseases with myocardial noradrenergic deficiency have been poorly understood. Here, we report evidence for one such mechanism-AS deposition within sympathetic noradrenergic neurons. We found that AS/TH colocalization indices postmortem in sympathetic ganglion tissue were associated with myocardial NE depletion and that AS/TH colocalization indices in vivo in skin biopsies were associated with neuroimaging evidence of cardiac sympathetic denervation and dysfunction in Lewy body nOH.
We validated and applied 2 approaches for quantitative analyses of sympathoneural AS deposition. The first was based on the fact that all 3 sympathetic noradrenergically innervated constituents in skin biopsies-arrector pili muscles, blood vessels, and sweat glands-can be delineated by SMA. Regions of interest were drawn based on the location of sympathetic noradrenergic fibers coursing parallel to SMA in arrector pili muscles, in the adventitia of blood vessels, and around secretory epithelial cells in sweat glands.
The second novel quantitative approach was calculation of the AS/TH colocalization index. We validated this index by analyzing postmortem images of sympathetic ganglion tissue. Compared with control subjects and patients with non-Lewy body forms of nOH, patients with autopsyproven Lewy body diseases had high AS/TH colocalization indices in sympathetic ganglion tissue. The AS/TH colocalization index in skin biopsies was validated by comparing patients diagnosed with Lewy body versus patients with rare non-Lewy body forms of nOH. All patients with Lewy body nOH had elevated AS/TH colocalization indices, in contrast with normal indices in most patients with nonLewy body nOH and healthy controls without a Lewy body disease or nOH.
By both the regions of interest and AS/TH colocalization index methods, Lewy body forms of nOH were characterized by AS deposition in sympathetic noradrenergically innervated skin constituents. For all 3 constituents, the patients with Lewy body nOH had many-fold higher AS signal intensities than did patients with non-Lewy body nOH and healthy controls. Because the AS/TH colocalization index data agreed with the regions of interest data for all 3 skin constituents (Table S1 ), a substantial proportion of AS signal seems to reflect AS deposition within sympathetic noradrenergic nerves.
Previous studies described elevated AS levels in skin biopsies from patients with PAF, 21, 46 PD, 21, 23, 47 and DLB 11 and normal levels in MSA 47 but without quantification of AS within sympathetic noradrenergic neurons. Our results agree generally with those in a recent report by Donadio et al 11 that Lewy body forms of synucleinopathy are associated with intraneuronal AS deposition in skin biopsies. That study used protein gene product 9.5, known as PGP 9.5, a nonspecific axonal marker, whereas ours used TH, a specific marker of sympathetic noradrenergic neurons. A key advantage of the current study was the quantitative methodology used to measure intraneuronal AS deposition.
Analyses of 18 F-dopamine-derived radioactivity over time enabled assessments of cardiac sympathetic innervations and intraneuronal catecholamine turnover in the same patients from whom skin biopsies were obtained. Peak radioactivity at about 8' after initiation of the 3-minute infusion of the tracer is a measure of neuronal uptake and, therefore, an indirect measure of innervations, and the mono-exponential slope of subsequent decline in radioactivity (k8'-25') is a measure of catecholamine turnover. 18 In confirmation of previous reports, 17, 18 we found that patients with Lewy body forms of nOH had evidence for both denervation and increased turnover. We now report that these abnormalities are associated with increased AS deposition in cutaneous sympathetic noradrenergic nerves. 
Limitations
The main limitations of this study relate to generalizability of the results and to the restricted focus on nOH. All the patients evaluated at the NIH Clinical Center were referred for possible autonomic synucleinopathy, were selected in terms of inclusion and exclusion criteria for one or more intramural National Institute of Neurological Disorders and Stroke research protocols, and agreed to undergo comprehensive inpatient research testing. The results from this study, therefore, might not apply to the broader population of patients with nOH. Because the study was designed to assess a specific mechanism-intraneuronal AS deposition-that might link AS with sympathetic noradrenergic deficiency in nOH, whether increased AS/TH colocalization occurs generally in Lewy body diseases independently of nOH cannot be determined from the present data.
Perspectives
We report strong associations of AS deposition in sympathetic noradrenergic nerves in sympathetic ganglion tissue with myocardial NE depletion and of intraneuronal AS deposition in skin biopsies with neuroimaging evidence of myocardial noradrenergic denervation and dysfunction in Lewy body forms of nOH. These associations raise the possibility that intraneuronal AS deposition may play a pathophysiological role in sympathetic noradrenergic neurodegeneration.
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